| Discuss | Index | Tracked By |
All Eyes on Dendreon Corp.
DNDN Linked by WallStNation.com ( track newsfeed | ignore newsfeed ) - February 09, 11:43AM from (wallstnation.com) Dendreon Corporation (NASDAQ:DNDN) could have an instant $1 billion in sales if the FDA votes to approve the company's cancer more ...
Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
ENZN Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 10:06AM from (www.businesswire.com) Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended more ...
OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010
OSIP Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 09, 10:00AM from (www.businesswire.com) OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its fourth quarter and year-end 2009 financial results will more ...
Cash Rich, No Debt Stocks
QLTI BIIB CHL LTON FACT Linked by Investopedia Stock Analysis ( track newsfeed | ignore newsfeed ) - February 08, 01:58PM from (stocks.investopedia.com) Anytime you can find a company with lots of cash and little or no debt, it's worth a closer look. more ...
Traders Send Select Stem Cell Shares Soaring
OPXA JNJ ABT NBS GILD PSTI BCRX NVAX ATHX GERN OSIR CUR Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 08, 10:30AM from (www.tickerspy.com) The absence of notable news didn't stop speculators in the stem cell sector on Monday. Select stem cell more ...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
NVGN MSHL NRT Linked by marketwire ( track newsfeed | ignore newsfeed ) - February 08, 08:00AM from (www2.marketwire.com) Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christopher Naughton had resigned as a member of the Board of Directors more ...
Vertex Pharma Reports Better-Than-Expected Q4 Loss of $0.66
VRTX Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 04:57PM from (www.streetinsider.com) more ...
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
VRTX Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 04, 04:04PM from (www.businesswire.com) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its late-stage development more ...
Swine Flu Antiviral Helps BioCryst Crush Estimates in Q4
BCRX APT RHHBY NVAX INO GNBT SVA NVS SNY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 04, 10:35AM from (www.tickerspy.com) While select swine flu players have seen their pops and drops, BioCryst Pharmaceuticals (BCRX) may have emerged as the small-cap champion of the 2009 pandemic. more ...
Hospira Tops Q4 Views; Guides FY10 EPS
HSP Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 07:49AM from (www.streetinsider.com) more ...
Hospira Reports Fourth-Quarter and Full-Year 2009 Results
HSP Posted by PR Newswire ( track newsfeed | ignore newsfeed ) - February 04, 07:27AM LAKE FOREST, Ill., Feb. 4 /PRNewswire-FirstCall/ -- Hospira, more ...
BioCryst Pharma Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
BCRX Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 06:51AM from (www.streetinsider.com) more ...
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
BCRX Posted by PR Newswire ( track newsfeed | ignore newsfeed ) - February 04, 06:45AM BIRMINGHAM, Ala., Feb. 4 /PRNewswire-FirstCall/ -- BioCryst more ...
ZymoGenetics to Host Conference Call and Webcast on February 11, 2010 to Discuss 2009 Year-end Financial Results
ZGEN Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 04, 06:00AM from (www.businesswire.com) ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will report fourth quarter and year-end 2009 financial results on more ...
Cytokinetics Tops Q4 EPS by 1c
CYTK Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 03, 04:01PM from (www.streetinsider.com) more ...
Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2009 Financial Results
CYTK Linked by marketwire ( track newsfeed | ignore newsfeed ) - February 03, 04:00PM from (www2.marketwire.com) Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $1.0 million more ...
Onyx Pharma initiated with "buy"
ONXX Linked by newratings ( track newsfeed | ignore newsfeed ) - February 03, 01:43PM from (www.newratings.com) NEW YORK, February 3 (newratings.com) - Analysts at Brean Murray initiate coverage of Onyx Pharma (ticker: ONXX) with a "buy" more ...
Lung Rx LLC, A Subsidiary Of United Therapeutics Corporation, And mondoBIOTECH holding AG Announce Today a Global Strategic Partnership Agreement for the Development Of Aviptadil Platform
UTHR Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 03, 01:34PM from (www.businesswire.com) United Therapeutics Corporation (NASDAQ: UTHR), und mondoBIOTECH holding AG (SIX: RARE) melden globale strategische Partnerschaft more ...
Home Diagnostics Buyout Powers Diabetes Segment
NVO AMLN HDIX MNKD GNBT ARRY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 03, 12:03PM from (www.tickerspy.com) Home Diagnositics (HDIX) is soaring today after the company announced a definitive merger agreement with Nipro Corporation. more ...
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
SGEN Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 03, 09:00AM from (www.businesswire.com) Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that more ...
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|